Effectiveness of the Personalized Responses & Integrated Systems for Metabolism (PRISM) on Improv… (NCT07710274) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Effectiveness of the Personalized Responses & Integrated Systems for Metabolism (PRISM) on Improving Insulin Resistance Among Adults With Metabolic Syndrome: A Pilot Study (PRISM-I)
Singapore200 participantsStarted 2026-07
Plain-language summary
The primary objective of the Personalized Responses \& Integrated Systems for Metabolism (PRISM-I) pilot study is to assess the feasibility of conducting a definitive randomized controlled trial evaluating precision lifestyle interventions for improving insulin resistance in adults with metabolic syndrome.
Who can participate
Age range
21 Years – 70 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
Participants will be included for if they are:
* (1) adults aged 21-70 years old;
* (2) willing and able to comply with using a CGM, smart ring, food logging app
* (3) able to provide written informed consent;
* (4) English-speaking and literate;
* (5) meet the inclusion criteria for metabolic syndrome and insulin resistance.
* The criteria for insulin resistance is HOMA-IR ≥ 2.5.
* The criteria for metabolic syndrome is to have high waist circumference (≥ 80cm for females and ≥ 90cm for males); and any two of the four below:
* (1) raised triglycerides: 1.7 mmol/L or on treatment;
* (2) reduced HDL cholesterol: \< 1.0 mmol/L (40 mg/dL) in men, \< 1.3 mmol/L (50 mg/dL) in women, or on treatment;
* (3) high blood pressure: 130/85 mmHg or on treatment; or
* (4) raised fasting glucose: 5.6 mmol/L (100 mg/dL) or previously diagnosed with T2DM
Exclusion Criteria:
Participants will be excluded from both phases if they are:
* (1) on insulin therapy;
* (2) are pregnant or lactating;
* (3) have a medical condition or are on a treatment that may interfere with study participation or metabolic assessments, as determined by the study investigators;
* (4) currently participating in other lifestyle modification programs.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)
Timeframe: At baseline, Week 10
Trial details
NCT IDNCT07710274
SponsorNational University Health System, Singapore